For Medical Device Founders
Most medical devices fail not on technology — they fail on regulatory strategy, clinical adoption, manufacturing scalability, and reimbursement pathways. The gaps that derail fundraising. We help you see them first, fix them first, then confidently raise.
Schedule AssessmentYour technology is strong. Our job is to make sure every investor, regulator, and partner sees the full picture — and says yes.
Currently accepting 4 new founder assessments per month: Each assessment receives full MD + BME attention from founders at every stage — from first prototype to Series B. Referred founders get priority scheduling. Check availability →
What We Assess
Your Vantage Assessment covers every gap that investors will find. In one integrated evaluation.
510(k) predicate strategy, classification risk, and FDA submission readiness assessed for speed and viability.
DFM completeness, supply chain viability, and production cost structure validated for commercialization.
Workflow integration, physician acceptance, and evidence gaps that block real-world adoption assessed directly.
CPT code pathways, payer coverage likelihood, and economic value proposition assessed for revenue viability.
Patent position strength, freedom-to-operate analysis, and competitive protection evaluated for investor confidence.
Regulatory, clinical, and commercial capability gaps assessed against VC expectations for execution risk.
Market maturity, payer readiness, and physician adoption capacity aligned for optimal launch window.
Your full position validated against what VCs and strategic investors will scrutinize pre-check and diligence.
Common Failure Points
Where device companies typically fail — and where Vantage Assessment catches risks before they cost 12-18 months and $1-3M
Wrong predicate choice → FDA rejection risk, 12-18 month delay
Can't scale under QSR → Cost overruns, quality failures
No reimbursement pathway → Market collapses post-launch
Vantage Assessment catches these failures at stage 3 or 4 — before you've locked engineering, invested in manufacturing, or hit clinical or regulatory walls. That's the difference between a 3-month pivot and an 18-month reset.
Why This Matters
75% of medical device startups fail.†5 Most don't fail on technology — they fail on regulatory strategy, reimbursement pathways, clinical adoption, and manufacturing scalability. These are the dimensions investors will probe in diligence. The gaps that kill fundraising momentum.
Advisors and mentors give you business strategy. Accelerators give you pitch coaching. Neither evaluates whether your device will actually be adopted by physicians, manufactured at scale, or reimbursed by payers. You're flying blind on the things that matter most.
How You Win
Investors screen 100+ deals per year. Without validated clinical-technical data, your pitch relies on narrative alone — and most get passed on.
A Vantage Score gives investors quantified, third-party validation of your clinical adoption potential, manufacturing readiness, and regulatory pathway — the exact risks they evaluate.
You walk into investor meetings with validated data, not just a pitch deck. The Vantage report becomes a credibility asset that differentiates you from other deal flow.
How We Help
Comprehensive assessment with a concrete roadmap to strengthen your company across regulatory, clinical, and commercial dimensions.
Our MD + BME team evaluates your company through the lens that stakeholders, strategic partners, and investors will use—identifying exactly what's working and what isn't so we can strengthen your position.
You get a detailed assessment, honest gaps, and a concrete remediation roadmap. Then you fix it before regulators, acquirers, or investors discover it. That's how strong companies are built.
How It Works
Your assessment moves through six integrated stages — each combining physician expertise with engineering rigor.
Your Vantage Score
Your Vantage Score quantifies your company's position across all critical dimensions on a 100-point scale. It identifies specific gaps, prioritizes remediation, and gives investors a validated third-party assessment of commercial viability.
A score of 70+ signals investor-readiness: regulatory clarity, clinical validation, manufacturing feasibility, and market positioning all de-risked. Below 70, you get an exact roadmap of what to fix and the sequence that matters most.
This replaces "trust us" with "here's the data."
Your Path to Investor Ready
The Vantage flywheel: assess, improve, prove, raise
Share your company info through our secure intake. We analyze regulatory, clinical, manufacturing, and commercial dimensions against our proprietary framework.
Receive your quantified score with specific findings. 70+ means investor-ready. Below 70, you get an exact roadmap of what to fix and how.
Address the gaps we've identified — clinical evidence, predicate strategy, IP position, or commercial model. You'll know exactly what to prioritize.
Re-score at a reduced rate. Show investors a before-and-after Vantage Score that proves you've de-risked. Our clients report significantly accelerated fundraising timelines.
What You'll Receive
A snapshot of your Vantage Assessment deliverable
Company Assessment
[Your Company Name]
Rating
Promising — Needs Development
Significant strengths with addressable gaps
Top 3 Findings
Regulatory pathway is sound
510(k) with strong predicate match
Score: 85/100
Clinical evidence insufficient for hospital adoption
Only bench data, no clinical validation
Score: 45/100
Reimbursement pathway unclear
No CPT code identified
Score: 52/100
Priority Actions
Initiate clinical feasibility study
$150-300K | 6-9 months
Engage reimbursement consultant for CPT code strategy
$25-50K
File provisional patent on manufacturing process improvement
Timeline: Immediate
Investor Readiness
Currently below threshold for institutional VC. With recommended improvements, projecting 70+ score within 6-9 months and Series A readiness.
Services & Pricing
Most founders start with the Full Company Assessment before fundraising. Quick Readiness Check works well for earlier-stage companies testing investor readiness.
Pre-seed to post-seed: Quick Readiness Check — understand your risk profile before approaching investors. Series A prep: Full Company Assessment — comprehensive scoring investors can reference. Pivoted or stalled: Strategic Reset — reassess after a significant change in approach.
Fast scan for early-stage founders
$5,000
1 week
Quick-scan across all dimensions, top 5 gaps identified, high-level remediation plan.
Complete diagnostic
$15,000
2-3 weeks
Complete Vantage Score covering all dimensions. Identifies every gap with detailed roadmap.
For companies pivoting
$5,000
1 week
Abbreviated score, top 3 growth areas, action roadmap for your next phase.
After you've made progress
$8,000
1-2 weeks (90+ days after initial)
Full re-assessment with before/after comparison. Demonstrates progress to investors.
Our Commitment: If our assessment doesn't identify at least one material risk that your current advisors haven't flagged, we refund the engagement in full.
Vantage Secure available. Founders in pre-acquisition or defense-adjacent situations may need our air-gapped tier with encrypted processing. Learn more →
Your Deliverable
Vantage Score
Comprehensive score across proprietary categories with actionable remediation roadmap
Top 3 Findings
510(k) predicate at risk
Recent FDA reclassification activity on your selected device means your predicate may no longer be valid. This requires immediate pathway reassessment before design lock.
Clinical adoption unclear
No physician workflow validation data. Stakeholders will flag this. Recommend immediate physician interviews and workflow mapping before next milestone.
Strong IP position
2 granted patents, FTO analysis clean. This is a real competitive advantage—make sure your investor pitch highlights the barrier to entry you've created.
Package Includes
After Your Assessment
Your assessment is step one. Here's what comes next.
Full report + 60-minute walkthrough. Review findings, scoring, and remediation priorities together.
Act on findings with optional specialist support for regulatory, manufacturing, or clinical work.
Baseline already built. Re-score after a pivot, milestone, or gap remediation at 40% off. Before-and-after Vantage Score becomes a pitch-deck asset.
Quarterly check-ins to update scores and strategy. $2,500/quarter for early clients. Investor referrals get first session free.
Your Vantage Score compounds. Your initial assessment creates a documented risk baseline. Each re-assessment after a milestone — FDA feedback, clinical data, pivot, or fundraise — captures your progress and produces a before-and-after comparison that becomes a fundraising asset. Investors see not just where you are, but how you respond to hard feedback. When to re-assess →
You absolutely do — and that deep expertise is your greatest asset. But the risks that derail medical device companies rarely live within a single domain. They live at the intersections: where your regulatory strategy meets reimbursement reality, where your clinical evidence meets physician workflow, where your manufacturing plan meets FDA quality system requirements.
A neural interface startup had a world-class engineering team and a clear 510(k) pathway. Their technology worked. What they hadn't assessed was that their predicate device strategy relied on a classification that the FDA had been quietly reconsidering. A Vantage-style cross-domain review would have flagged this 18 months before it became a $2M regulatory reset.
The question isn't whether you know your technology. It's whether you can see the full picture across all evaluation dimensions simultaneously — the way investors, acquirers, and regulators will.
Scenario based on documented regulatory outcome patterns. Details composited.
Free Tool
10 questions. 2 minutes. Understand where you stand across the key dimensions investors evaluate.
We don't invest in device companies, sit on boards, or hold equity. We're not pushed by relationships with regulators, manufacturers, or investors. Our only incentive is to tell you the truth — the clinical, regulatory, and commercial reality your company faces — so you can make better decisions.
What this means: You get an honest assessment focused entirely on your company's success, free from conflicts of interest or hidden agendas. When we identify gaps, we identify them because they matter — not because they create future work for us.
Resources for Founders
Learn from patterns across hundreds of medical device companies
10 red flags that predict medical device failure. Check your development path against documented patterns.
DownloadThe regulatory blind spots that cost founders 6–12 months and $500K+ to fix after submission.
ReadThe clinical, regulatory, and commercial questions that determine whether VCs write checks.
ReadPracticing physician and Medical Director at Adventist Health White Memorial. Chairs P&T Committee evaluating device adoption for 150+ physicians. Understands firsthand why physicians adopt — or reject — new devices.
BS Biomedical Engineering, UC Irvine; MSE Quality, Reliability & Statistical Engineering, ASU. Part of the Axonics operations engineering team that navigated the regulatory and manufacturing path leading to Boston Scientific's $4.1B acquisition.
Common Questions
Yes. Our Quick Readiness Check ($5K) is designed for pre-revenue companies preparing for investor conversations. The earlier you understand your clinical-technical risk profile, the better positioned you are to address gaps before investors find them.
Better to know now than during a fundraise. A "fatal flaw" finding is rare — most risks are addressable with the right plan and timeline. Your report will include specific remediation steps and realistic timelines. Many founders use unfavorable findings to pivot strategy before burning capital on a flawed approach.
Your assessment report is yours — no licensing fees, no restrictions. Include it in data rooms, reference the score in pitch decks, or share the executive summary with prospective investors. A strong Vantage Score (70+) signals that an independent clinical-technical assessment has validated your approach.
Post-seed through Series A prep: Start with Quick Readiness Check ($5K). Series A through Series B prep: Full Company Assessment ($15K) for comprehensive scoring. Post-fundraise or pivoting: Strategic Reset ($5K) if your approach has changed. The Vantage Score is designed to evolve with your company.
Quick Readiness Check: 5-7 business days. Full Company Assessment: 10-15 business days. Strategic Reset: 5-7 business days. We work on your timeline — if you have an investor meeting in 3 weeks, tell us and we'll prioritize accordingly.
From Our Research
Frameworks for navigating regulatory, clinical, and commercial risk before investors ask.
Common regulatory missteps that add 12-18 months to your path — and how to avoid them.
ReadBeyond the pitch deck — the clinical, regulatory, and manufacturing questions sophisticated investors ask.
ReadWhy your predicate device selection matters more than you think — and how to validate it before submission.
ReadFind the gaps. Fix them. Then confidently talk to investors—or just build a better product.
Not sure if you need an assessment? In a free 20-minute call, we'll identify the 3 biggest risks in your device category — no cost, no obligation.
†1-4 Vantage proprietary findings based on retrospective analysis of documented medical device outcomes. †5 Proximo Medical; MDDI Online. †6 MedDevice Online.